COVID-19 Critical Care Consortium Observational Study Incorporating the Extracorporeal Membrane Oxygenation for 2019 Novel Coronavirus Acute Respiratory Disease (ECMOCARD)
Extracorporeal Life Support Organisation
10,000 participants
Mar 5, 2020
Observational
Conditions
Summary
We hypothesize that a significant percentage of patients with suspected or confirmed COVID-19 infection will require admission to the intensive care unit, mechanical ventilation and ECMO for refractory hypoxemia., In addition, it is hypothesized that a substantial proportion of patients will also present with concurrent coagulation disorders and thrombosis. Objectives: To describe clinical features; severity of pulmonary dysfunction; incidence of ICU admission and use of mechanical ventilation, coagulatory and thrombotic derangement, and ECMO technical characteristics; duration of ECMO; complications; and survival of patients with suspected or confirmed COVID-19.
Eligibility
Inclusion Criteria2
- Clinical suspicion or laboratory-confirmed COVID-19 infection by real-time PCR and/or next-generation sequencing
- Admission to an intensive care unit
Exclusion Criteria2
- Patients treated with mechanical ventilation for other concomitant causes.
- Patients treated with ECMO for other concomitant causes
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In patients with suspected or confirmed 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in effect a large-scale clinical audit during a global health emergency, as all data is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. Retrospective data will be sourced from all collaborating hospitals across Australia from January 2020 to March 2020. Whereas, international hospitals will provide their retrospective data between January 2019 and march 2020. Prospective data will be collected in Australian and International hospitals until completion of COVID-19 global epidemic, as judged by the World Health Organization. The total duration of observation per participant will be until hospital discharge or 28 days post intensive care unit admission, whichever comes later. The study will combine prospective observation, and retrospective observations sourced from clinical charts.
Locations(45)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620000421932